Venclexta (venetoclax)

Numéro de dossier de l’APP: 21564
État des négociations:
Negotiations were not pursued
Indication(s):
Venclexta in combination with low-dose cytarabine is indicated for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy
Promoteur/fabricant:
AbbVie Corporation
Numéro de projet de l’ACMTS:
PC0239-000
Lettre-contrat de l’APP:
Not Applicable
Conclusion du processus de négociation: